Glenmark Launches RYALTRIS Nasal Spray in Brazil

Glenmark Pharmaceuticals Ltd. announced the launch of its RYALTRIS® Nasal Spray in Brazil through its subsidiary, Glenmark Specialty S.A. This launch follows regulatory approval from ANVISA and introduces a dual-action therapy for allergic rhinitis, combining olopatadine and mometasone furoate. Brazil represents a significant market in Latin America, with an estimated 20-30% of its population affected by allergic rhinitis. RYALTRIS® is Glenmark's first globally commercialized innovative product and is now approved in 57 markets worldwide.